CA
VRX

Cullinan Associates’s VALEANT PHARMACEUTICALS INTL VRX Stock Holding History

Cullinan Associates’s Portfolio VRX Stock Details VRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-46,500
Closed -$1.08M – 183
2018
Q2 		$1.08M Buy
46,500
+500
+1% +$11.6K 0.08% 124
2018
Q1 		$732K Buy
46,000
+1,000
+2% +$15.9K 0.06% 143
2017
Q4 		$935K Buy
+45,000
New +$935K 0.07% 133

Cullinan Associates's VRX Position: Q3 2018 in Review

Cullinan Associates sold out of VALEANT PHARMACEUTICALS INTL (VRX) in Q3 2018, closing a stake of 46,500 shares — an estimated $1.08M sold.

Cullinan Associates first reported a position in VRX in Q4 2017 and held it in 3 quarters. The position peaked at $1.08M in Q2 2018. 0 funds tracked by Wall St. Rank hold VRX as of Q3 2018.

  • Cullinan Associates reported no remaining VALEANT PHARMACEUTICALS INTL position as of Q3 2018 after selling out during the quarter.
  • Cullinan Associates sold 46,500 VALEANT PHARMACEUTICALS INTL shares in Q3 2018, an estimated $1.08M.
  • Cullinan Associates first reported a position in VALEANT PHARMACEUTICALS INTL in Q4 2017 and held it in 3 quarters.
  • Cullinan Associates's VALEANT PHARMACEUTICALS INTL position peaked at $1.08M in Q2 2018.
  • 0 funds tracked by Wall St. Rank held VALEANT PHARMACEUTICALS INTL as of Q3 2018.

Based on Cullinan Associates's 13F filing for Q3 2018, filed 19 Oct 2018.